<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04716595</url>
  </required_header>
  <id_info>
    <org_study_id>K-877-ER-03</org_study_id>
    <nct_id>NCT04716595</nct_id>
  </id_info>
  <brief_title>A Phase III Long Term Study of K-877 Extended Release Tablet</brief_title>
  <official_title>A Phase III Long Term Study of K-877 Extended Release Tablet-A Multicenter, Randomized, Open Label, Parallel Group Trial in Patients With Dyslipidemia With High TG-</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kowa Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kowa Company, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the safety and efficacy of K-877 Extended Release (ER) once daily for 52 weeks&#xD;
      in the morning or evening in dyslipidema.The starting dose of the ER tablet will be 0.2&#xD;
      mg/day. If the efficacy is insufficient, it will investigate the safety and efficacy of 0.4&#xD;
      mg/day.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy : Mean of percent change from baseline in fasting serum TG (mg/dL) at the time of final evaluation* and immediately before it * : Week 52 or at discontinuation</measure>
    <time_frame>Final evaluation (Week 52 or at discontinuation) and immediately before it</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy : Mean of percent change from baseline in fasting serum Total Cholesterol (mg/dL) at the time of final evaluation* and immediately before it * : Week 52 or at discontinuation</measure>
    <time_frame>Final evaluation (Week 52 or at discontinuation) and immediately before it</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy : Mean of percent change from baseline in fasting serum LDL-C (mg/dL) at the time of final evaluation* and immediately before it * : Week 52 or at discontinuation</measure>
    <time_frame>Final evaluation (Week 52 or at discontinuation) and immediately before it</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy : Mean of percent change from baseline in fasting serum HDL-C (mg/dL) at the time of final evaluation* and immediately before it * : Week 52 or at discontinuation</measure>
    <time_frame>Final evaluation (Week 52 or at discontinuation) and immediately before it</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy : Mean of percent change from baseline in fasting serum non-HDL-C (mg/dL) at the time of final evaluation* and immediately before it * : Week 52 or at discontinuation</measure>
    <time_frame>Final evaluation (Week 52 or at discontinuation) and immediately before it</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>morning administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>K-877 ER 0.2 mg/day morning administration (once daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>evening administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>K-877 ER 0.2 mg/day evening administration (once daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-877 ER 0.2 mg/day morning administration (once daily)</intervention_name>
    <description>K-877 ER 0.2 mg tablet</description>
    <arm_group_label>morning administration</arm_group_label>
    <other_name>Pemafibrate ER 0.2 mg/day morning administration (once daily)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-877 ER 0.2 mg/day evening administration (once daily)</intervention_name>
    <description>K-877 ER 0.2 mg tablet</description>
    <arm_group_label>evening administration</arm_group_label>
    <other_name>Pemafibrate ER 0.2 mg/day evening administration (once daily)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with dyslipidemia had to be age 20 years or older at written informed consent&#xD;
&#xD;
          2. Patients who have received dietary or exercise guidance from 12 weeks or more prior to&#xD;
             Screening&#xD;
&#xD;
          3. Patients with the fasting serum TG &gt;= 150 mg/dL twice consecutively at Screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a fasting serum TG &gt; 1000 mg/dL at Screening&#xD;
&#xD;
          2. Patients who require administration of prohibited drugs during the clinical trial&#xD;
             period after written informed consent&#xD;
&#xD;
          3. Patients with uncontrolled thyroid disease&#xD;
&#xD;
          4. Patients with type 1 diabetes and uncontrolled diabetes [HbA1c(NGSP) &gt;= 10.0 % at&#xD;
             Screening]&#xD;
&#xD;
          5. Patients with uncontrolled hypertension (SBP &gt;= 160 mmHg or DBP &gt;= 100 mmHg)&#xD;
&#xD;
          6. Patients with an AST or ALT three times the upper limit at Screening&#xD;
&#xD;
          7. Patients with an CK five times the upper limit at Screening&#xD;
&#xD;
          8. Patients with cirrhosis or those with biliary obstruction&#xD;
&#xD;
          9. Patients with acute myocardial infarction within 3 months before obtaining informed&#xD;
             consent&#xD;
&#xD;
         10. Patients with heart failure class III or higher according to NYHA cardiac function&#xD;
             classification&#xD;
&#xD;
         11. Patients with malignant tumor or those who are judged to have a high risk of&#xD;
             recurrence&#xD;
&#xD;
         12. Patients with a history of serious drug allergies (anaphylactic shock, etc.)&#xD;
&#xD;
         13. Pregnant women, lactating women, women planning to become pregnant or lactating during&#xD;
             the study period, or pregnant women who do not use specific contraceptive methods&#xD;
&#xD;
         14. Patients who have collected 400 mL or more of whole blood within 16 weeks, or 200 mL&#xD;
             or more of whole blood within 4 weeks, or blood samples (plasma and platelet&#xD;
             components) within 2 weeks before Screening&#xD;
&#xD;
         15. Patients who have received K-877 (pemafibrate)&#xD;
&#xD;
         16. Patients who participate in other clinical trials at the time of written informed&#xD;
             consent and who received medication or who have received clinical trials other than&#xD;
             placebo for less than 16 weeks&#xD;
&#xD;
         17. Patients who have been determined inappropriate by the investigator, etc&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Saiseikai Futsukaichi Hospital</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Takasaki General Medical Center</name>
      <address>
        <city>Gunma</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hasegawa Medicine Clinic</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japan Community Health care Organization Hokkaido Hospital</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minami Akatsuka Clinic</name>
      <address>
        <city>Ibaraki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Yokohamashi Nanbu Hospital</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinugawa Cardiology Clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyosokai AMC NISHI-UMEDA Clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical corporation Tani clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shiraiwa medical clinic</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cosmos medical corporation Aozora total clinic</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akasaka Chuou Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Corporation Chiseikai Tokyo Center Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shimokitazawa Tomo Clinic</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>January 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 20, 2021</study_first_posted>
  <last_update_submitted>June 16, 2021</last_update_submitted>
  <last_update_submitted_qc>June 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

